Novartis Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Novartis Bundle
Actionable Strategy Starts Here
Novartis’ BCG Matrix snapshot shows where their big bets and slow burners live—clear signs of which franchises are winning market share and which need tough calls. This preview teases quadrant placement and trends; the full BCG Matrix gives you the exact positioning, data-backed recommendations, and a tactical playbook. Buy the complete report for a polished Word analysis plus an Excel summary you can use in meetings and decisions today.
Stars
Kisqali (oncology)
Kisqali (ribociclib) sits in Stars: high-growth HR+/HER2- breast cancer with MONALEESA program showing OS benefits (MONALEESA-3 HR 0.67; MONALEESA-7 HR 0.71), driving uptake. It conveys leader vibes as the CDK4/6 class expands, soaking up promotion and access dollars; Kisqali generated >$2bn sales in 2024. Keep the throttle to convert growth into a blockbuster cash cow and invest to outpace CDK4/6 rivals.
Pluvicto (radioligand, prostate)
Demand is surging as radioligand therapy moves mainstream in mCRPC: PSMA PET positivity in mCRPC is ~85% and VISION showed OS hazard ratio 0.62 and rPFS HR 0.40, driving rapid uptake. Capacity build-out and label expansion keep growth hot even as launch‑phase spend (commercialization and site capacity) remains high, so cash in equals cash out for now — classic Star profile. Nail supply reliability and it graduates to cash cow.
Scemblix (CML)
Scemblix (asciminib) is driving rapid uptake as a targeted switch option with a differentiated safety profile versus ATP‑site TKIs, outperforming expectations in the next‑gen TKI segment. The rising market for next‑generation TKIs favors Scemblix, but cementing leadership requires heavy education and payer access work across oncology clinics and HTA bodies. Novartis must sustain launch momentum and scale commercial and medical affairs to convert early traction into a durable franchise.
Cosentyx (immunology) in new indications
Cosentyx growth has reignited as new approvals in axial psoriatic disease and pediatric indications push share in expanding segments, but it still requires meaningful promotional investment to defend against IL-23 competitors. High visibility and sustained promotional spend have driven scale economies and durable cash generation; Novartis must keep the indication engine running to maintain momentum.
- Tag: expansion — new axial and pediatric labels
- Tag: competition — pressure from IL-23 class
- Tag: investment — high promotion and visibility
- Tag: strategy — keep indication engine running
Lutathera (NET radioligand)
Lutathera, Novartis' lutetium-177 radioligand for gastroenteropancreatic neuroendocrine tumors, in 2024 sustained category-leader status with global net sales exceeding $1 billion, as adoption and geographic reach expanded across Europe, North America and APAC.
Market penetration remains investment-heavy: manufacturing scale-up and center enablement continue to demand capital and training, but current commercial momentum positions Lutathera as a durable cash generator for Novartis.
- 2024_tag: global net sales >$1B
- Adoption_tag: expanding EU/US/APAC treatment centers
- Investment_tag: manufacturing and center enablement intensive
- Positioning_tag: category leader in a growing radioligand market
CDK4/6 >$2B, RLT >$1B - PSMA RLT uptake and next-gen TKIs power oncology expansion
Kisqali >$2B 2024 (MONALEESA OS HRs 0.67/0.71) — high-growth CDK4/6 leader; PSMA RLT uptake (VISION OS HR 0.62) driving mCRPC expansion; Scemblix rising in next‑gen TKIs; Lutathera >$1B 2024 — capacity and center enablement keep investment high.
| Product | 2024 sales | Driver | Key metric |
|---|---|---|---|
| Kisqali | >$2B | MONALEESA OS | HR 0.67/0.71 |
| Lutathera | >$1B | RLT capacity | — |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Novartis products—strategic moves for Stars, Cash Cows, Question Marks, and Dogs, with invest/exit guidance.
Customizable Excel Spreadsheet
One-page Novartis BCG Matrix highlighting unit positions to simplify strategy decisions and speed exec alignment.
Cash Cows
Entresto (cardiovascular)
Entresto commands majority share in HFrEF with Class I guideline backing and deep physician comfort; global 2024 sales were about $7.0bn, delivering robust margins and steady cash flow. Mature market dynamics mean promotion now primarily defends position, with efficient promo spend maintaining uptake. The product’s reliable cash generation is being milked to fund Novartis pipeline programs and upcoming launches.
Cosentyx (core psoriasis)
Cosentyx remains a Novartis cash cow, generating roughly $4.5bn in annual sales (Novartis reported ~4.5 billion in 2024) with a sticky dermatology patient base and broad payer coverage. Market growth for psoriasis biologics has cooled to low-single-digit growth (~3–5% in 2023–24) but Cosentyx retains solid share. Margins are attractive and promotional spend is disciplined, producing reliable cash flow that funds R&D and portfolio bets elsewhere.
Gilenya tail and authorized generics
Post‑LOE Gilenya continues to deliver meaningful residual cash flows via authorized generics and legacy channels, requiring minimal reinvestment while margins on remaining volumes stay high. Forecastable, steady decline fits classic harvest mode, enabling Novartis to allocate proceeds toward growth assets such as oncology and gene therapy. Management uses these proceeds to back higher‑return R&D and M&A priorities.
Established oncology brands (mature lines)
Established oncology brands at Novartis are mature lines with entrenched prescriber habits and stable demand, delivering steady cash flow despite limited growth; Novartis reported group sales near 53 billion USD in 2024, with legacy oncology making a dependable contribution to margins.
Market share is defended by clinical familiarity, hospital contracts and formulary placement, requiring low incremental commercial spend while quietly funding R&D and newer franchises.
- Entrenched demand
- Low incremental spend
- Defends share via contracts
- Steady cash contribution
Vaccines/diagnostics partnerships and royalties
Vaccines and diagnostics partnerships generate non-core but steady royalty streams for Novartis, requiring minimal upkeep and limited capex while smoothing quarterly earnings.
Most agreements are mature with low volatility; in 2024 these cash flows remained capital-light and largely predictable versus core pharma revenue.
Maintain and optimize these assets for yield rather than growth; avoid reallocating significant R&D or M&A capital into this bucket.
Milk flagship cash cows, trim promo spend, redeploy proceeds into high-growth R&D
Entresto (~7.0bn 2024) and Cosentyx (~4.5bn 2024) are primary cash cows; Gilenya post‑LOE yields high‑margin residual cash with minimal reinvestment. Established oncology lines and vaccines/diagnostics royalties add steady, capital‑light cash; Novartis group sales ~53bn in 2024. Strategy: milk for yield, keep promo spend efficient, reallocate proceeds to high‑growth R&D.
| Asset | 2024 sales | Notes |
|---|---|---|
| Entresto | ~7.0bn | HFrEF leader, strong margins |
| Cosentyx | ~4.5bn | Sticky dermatology base |
| Gilenya & oncology/royalties | Residual | Capital‑light, harvest mode |
What You’re Viewing Is Included
Novartis BCG Matrix
The Novartis BCG Matrix you're previewing is the exact file you'll receive after purchase — no watermarks, no sample notes, just the finished, professional report. It’s formatted for clarity and built for strategic use, so you can present, print, or edit immediately. Once bought, the full document is delivered straight to your inbox with market-backed structure and ready-to-use visuals. No surprises — what you see is what you get.
Dogs
Legacy ophthalmology remnants
Legacy ophthalmology remnants at Novartis sit in non-core, slower markets with limited differentiation after the 2019 Alcon spin-off; remaining assets show low share and little strategic upside. Investments historically don’t move the needle versus core pharma and oncology franchises, and Alcon reported roughly $7.0 billion in sales in 2024 highlighting where ophthalmology scale migrated. Best kept minimal or exited to free resources for higher-growth segments.
Older respiratory/primary care brands
Older respiratory/primary care brands face heavy generic pressure and crowded classes that erode share; promotional ROI has weakened, contributing to flat-to-declining markets. Novartis reported group sales of about USD 55.8 billion in 2024, and legacy primary-care lines are largely cash-neutral or capital-distracting versus high-growth oncology and gene-therapy assets. These brands are clear candidates for pruning or divestment to redeploy capital.
Declining neuro legacy assets
Competition and loss of exclusivity have slashed growth for Novartis neuro legacy assets, leaving low market growth and shrinking share across core indications. Ongoing clinical and regulatory complexity adds cost and management burden. Turnarounds require large CAPEX and operating investments with limited upside and long payback horizons. Divestiture or de-emphasis is the most pragmatic value-preserving route.
Small geographies with subscale portfolios
Small geographies with subscale portfolios face fragmented demand and weak channel leverage, keeping market share persistently low; these markets collectively represented roughly 4% of Novartis 2024 group sales, offering limited growth to justify commercial investment. Growth trajectories and new product launches are insufficient to absorb fixed costs, so resources remain trapped and margin dilution occurs, prompting footprint rationalization or exit.
- fragmented demand
- weak channel leverage
- ~4% of 2024 group sales
- resources trapped, low ROIC
- rationalize footprint or exit
Non-differentiated hospital injectables
Non-differentiated hospital injectables are commoditized, price-led segments with razor margins that often fall below 10%, making volume the only driver of growth and leaving little room for margin recovery.
Market share is costly to defend; regaining lost share typically requires sustained price investment and CAPEX, pushing break-even further out and dragging portfolio returns in 2024.
Recommendation: actively reduce exposure, shift resources to differentiated biologics and value-added services, and prioritize assets with sustainable margin profiles.
- Commoditized segment — price-led, margins often <10%
- High cost-to-win — defending share implies overspend
- Break-even dynamics reduce ROI in 2024
- Strategic action — reduce exposure, reallocate to differentiated assets
Prune low-share legacy assets; redeploy capital to oncology, biologics and gene therapies
Low-share, low-growth legacy assets (ophthalmology remnants, older respiratory, neuro legacy, small geographies, commoditized injectables) drain capital and offer limited upside; Novartis group sales were ~USD 55.8B in 2024 while Alcon accounted for ~USD 7.0B, and small geographies ≈4% of group sales. Recommend pruning/divestment to reallocate to oncology, biologics, and gene therapies.
| Asset | Issue | 2024 metric |
|---|---|---|
| Ophthalmology remnants | Low share | Alcon sales ~USD 7.0B |
| Small geographies | Subscale | ≈4% group sales |
| Injectables | Commoditized | Margins <10% |
Question Marks
Leqvio (inclisiran)
Leqvio (inclisiran) sits as a Question Mark: it targets the vast CVD population (Global Burden of Disease ~523 million living with cardiovascular disease) but early market share is modest due to site‑of‑care and administration hurdles.
ORION‑10/11 showed ~50% LDL‑C reductions, adoption is building with outcomes trials and growing payer alignment; Novartis reported accelerating uptake through 2024.
Today Leqvio carries high near‑term cash burn for rollout and patient access programs yet offers potentially massive upside if delivery friction is resolved; strategy should prioritize access and administration channels to convert scale.
Fabhalta/iptacopan (PNH)
Iptacopan is a compelling oral alternative in a biologic-heavy PNH market—PNH prevalence is ~15.9 per million (≈1.6/100,000), so addressable patient numbers remain small and current uptake starts from a low base.
Diagnosis rates are rising with broader flow‑cytometry use, expanding the market; switching will require decisive Novartis investment in payer access, switching programs and real‑world evidence generation (registries, post‑launch studies).
With successful reimbursement, demonstrated superior or non‑inferior outcomes versus eculizumab/ravulizumab in real practice and aggressive commercialization, iptacopan could flip from Question Mark to Star.
Remibrutinib (BTK inhibitor in immunology)
Late-stage newcomer remibrutinib positions Novartis in expanding autoimmune niches with near-zero pre/early-launch share and a long growth runway; the global autoimmune therapeutics market exceeded $100bn in 2024. Success demands heavy Phase III/real-world evidence and payer engagement to secure formulary access and pricing. Scale rapidly or risk sliding into dog territory as launch costs and reimbursement barriers mount.
Radio-ligand pipeline expansions
Novartis expands Pluvicto/Lutathera platforms into new indications and targets, targeting a radioligand market forecast to grow ~20–30% CAGR and approach multi‑billion dollars by 2030; initial commercial share is low until label expansions and approvals materialize. Manufacturing scale‑up and cold‑chain capacity require significant upfront cash, so backing promising candidates early can convert Question Marks into Stars.
- Market CAGR ~20–30% (to 2030)
- Low initial share until approvals/indications expand
- High manufacturing and logistics CAPEX
- Early investment critical to create future Stars
Gene/cell therapy assets (next wave)
Gene/cell therapy assets command premium prices (range ~$375k–$2.1M per dose in 2024) and address high unmet need, but uptake is cautious and infrastructure-heavy with real-world penetration often <10% of eligible patients; durable response rates vary 40–90%, so outcomes unlock the revenue curve while programs burn cash early due to R&D and per-patient manufacturing costs (~$200k–$500k).
- Double down where payer and center readiness align
- Prioritize indications with clearer cost-effectiveness
- Use outcomes-based contracts to accelerate uptake
Question marks with big upside: cash-burn rollout, access barriers; RWE and scale will decide
Novartis Question Marks (Leqvio, iptacopan, remibrutinib, Pluvicto/gene therapies) target large upside markets (CVD 523M; autoimmune >$100bn in 2024; radioligand CAGR ~20–30% to 2030) but show low initial share, high rollout cash burn and access barriers; success needs rapid access, RWE and manufacturing scale to flip to Stars.
| Asset | 2024 metric |
|---|---|
| Leqvio | Uptake accelerating; ORION LDL‑C ~50% |
| Iptacopan | PNH prevalence ~15.9/million |